Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada.
Patterson Companies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$31.41|
|52 Week High||US$22.15|
|52 Week Low||US$37.37|
|1 Month Change||5.05%|
|3 Month Change||-9.09%|
|1 Year Change||28.73%|
|3 Year Change||23.47%|
|5 Year Change||-33.43%|
|Change since IPO||1,492.62%|
Recent News & Updates
Here's Why We Think Patterson Companies, Inc.'s (NASDAQ:PDCO) CEO Compensation Looks Fair for the time being
Performance at Patterson Companies, Inc. ( NASDAQ:PDCO ) has been reasonably good and CEO Mark Walchirk has done a...
Return Trends At Patterson Companies (NASDAQ:PDCO) Aren't Appealing
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
|PDCO||US Healthcare||US Market|
Return vs Industry: PDCO underperformed the US Healthcare industry which returned 33% over the past year.
Return vs Market: PDCO underperformed the US Market which returned 33.7% over the past year.
Stable Share Price: PDCO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PDCO's weekly volatility (5%) has been stable over the past year.
About the Company
Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. It operates through three segments; Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems.
Is Patterson Companies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PDCO ($31.41) is trading below our estimate of fair value ($66.01)
Significantly Below Fair Value: PDCO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PDCO is good value based on its PE Ratio (18.4x) compared to the US Healthcare industry average (22.5x).
PE vs Market: PDCO is poor value based on its PE Ratio (18.4x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: PDCO is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: PDCO is good value based on its PB Ratio (3.1x) compared to the US Healthcare industry average (3.3x).
How is Patterson Companies forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDCO's forecast earnings growth (6.7% per year) is above the savings rate (2%).
Earnings vs Market: PDCO's earnings (6.7% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: PDCO's earnings are forecast to grow, but not significantly.
Revenue vs Market: PDCO's revenue (2.1% per year) is forecast to grow slower than the US market (9.7% per year).
High Growth Revenue: PDCO's revenue (2.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PDCO's Return on Equity is forecast to be low in 3 years time (16.4%).
How has Patterson Companies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDCO has a high level of non-cash earnings.
Growing Profit Margin: PDCO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PDCO's earnings have declined by 47.5% per year over the past 5 years.
Accelerating Growth: PDCO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PDCO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (32.2%).
Return on Equity
High ROE: PDCO's Return on Equity (16.8%) is considered low.
How is Patterson Companies's financial position?
Financial Position Analysis
Short Term Liabilities: PDCO's short term assets ($1.6B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: PDCO's short term assets ($1.6B) exceed its long term liabilities ($702.4M).
Debt to Equity History and Analysis
Debt Level: PDCO's debt to equity ratio (65.3%) is considered high.
Reducing Debt: PDCO's debt to equity ratio has reduced from 80.7% to 65.3% over the past 5 years.
Debt Coverage: PDCO's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: PDCO's interest payments on its debt are well covered by EBIT (22.5x coverage).
What is Patterson Companies's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PDCO's dividend (3.31%) is higher than the bottom 25% of dividend payers in the US market (1.34%).
High Dividend: PDCO's dividend (3.31%) is low compared to the top 25% of dividend payers in the US market (3.58%).
Stability and Growth of Payments
Stable Dividend: PDCO's dividends per share have been stable in the past 10 years.
Growing Dividend: PDCO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (60.3%), PDCO's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PDCO's dividends in 3 years are forecast to be well covered by earnings (45.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Walchirk (55 yo)
Mr. Mark S. Walchirk has been the Chief Executive Officer and President of Patterson Companies, Inc. since November 20, 2017. Mr. Walchirk served as the President of U.S. Pharmaceutical at McKesson Corpora...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD4.76M) is about average for companies of similar size in the US market ($USD5.25M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Experienced Management: PDCO's management team is considered experienced (3.6 years average tenure).
Experienced Board: PDCO's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
Patterson Companies, Inc.'s employee growth, exchange listings and data sources
- Name: Patterson Companies, Inc.
- Ticker: PDCO
- Exchange: NasdaqGS
- Founded: 1877
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: US$3.054b
- Shares outstanding: 97.23m
- Website: https://www.pattersoncompanies.com
Number of Employees
- Patterson Companies, Inc.
- 1031 Mendota Heights Road
- Saint Paul
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 22:50|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.